Early Postoperative Dupilumab After Revision Endoscopic Sinus Surgery for CRSwNP: A Real-World Single-Centre Study
Journal of Clinical Medicine · 15.04.2026 · 15 (8) · 3015
DOI: 10.3390/jcm15083015 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 15.04.2026. Verfasst von Juan David Gutiérrez-Posso und 1 weiteren Autor:innen. Beteiligte Einrichtung: Otorhinolaryngology Department, Basurto University Hospital, OSI-Bilbao Basurto, 48013 Bilbao, Spain. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: IIS Biobizkaia.
Abstract (Originalsprache)
Background/Objectives: Chronic rhinosinusitis with nasal polyps (CRSwNP) is a type 2 inflammatory disease frequently associated with recurrence after endoscopic sinus surgery (ESS). Although biologic therapies such as dupilumab have demonstrated efficacy in severe CRSwNP, the optimal timing of treatment initiation in relation to surgery remains unclear. This study aimed to evaluate the clinical outcomes of early postoperative initiation of dupilumab after revision ESS using a multidimensional assessment of disease control.
Methods
This retrospective observational study included adult patients with severe CRSwNP treated with dupilumab at a tertiary referral centre. All patients had undergone at least two previous ESS procedures and initiated dupilumab within 30 days following revision surgery. Clinical outcomes were assessed at baseline and after 12 months, including Nasal Polyp Score (NPS), Sinonasal Outcome Test-22 (SNOT-22), nasal congestion and olfactory visual analogue scale (VAS) scores, and asthma control in patients with comorbid asthma. Treatment response was evaluated using a multidomain assessment.
Results
Ten patients were included. After 12 months, significant improvements were observed in NPS (from 4.7 ± 2.3 to 0.4 ± 1.0; p = 0.0019) and SNOT-22 (from 61.9 ± 17.3 to 26.5 ± 14.7; p = 0.0019). Nasal congestion and olfactory VAS scores also improved significantly. Most patients (70%) achieved an excellent multidimensional response, while 30% showed a moderate response. No patients required systemic corticosteroids or revision surgery during follow-up.
Conclusions
Early postoperative initiation of dupilumab after revision ESS was associated with improvements in endoscopic findings, symptom severity, and quality of life. These findings suggest that the early postoperative period may represent a therapeutic window in selected patients with severe recurrent CRSwNP. However, results should be interpreted with caution and considered hypothesis-generating.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Otorhinolaryngology Department, Basurto University Hospital, OSI-Bilbao Basurto, 48013 Bilbao, Spain.
- BioBizkaia Health Research Institute, 48903 Barakaldo, Spain.
ORCID-Profile: Juan David Gutiérrez-Posso
Förderung
- IIS Biobizkaia
Zitieren
APA
Gutiérrez-Posso, J. D., & Zabala-López de Maturana, A. (2026). Early Postoperative Dupilumab After Revision Endoscopic Sinus Surgery for CRSwNP: A Real-World Single-Centre Study. Journal of Clinical Medicine, 15(8), 3015. https://doi.org/10.3390/jcm15083015
Vancouver
Gutiérrez-Posso JD, Zabala-López de Maturana A. Early Postoperative Dupilumab After Revision Endoscopic Sinus Surgery for CRSwNP: A Real-World Single-Centre Study. Journal of Clinical Medicine. 2026;15(8):3015. doi:10.3390/jcm15083015
BibTeX
@article{GutirrezPosso2026,
author = {Gutiérrez-Posso, Juan David and Zabala-López de Maturana, Aitor},
title = {Early Postoperative Dupilumab After Revision Endoscopic Sinus Surgery for CRSwNP: A Real-World Single-Centre Study},
journal = {Journal of Clinical Medicine},
year = {2026},
volume = {15},
number = {8},
pages = {3015},
doi = {10.3390/jcm15083015}
}
EUVIMED